Nycomed News RSS feedhttp://www.tpi.takeda.com/media/mediaenhttp://www.tpi.takeda.com/~/media/Countries/www_nycomed_com/Settings/img_logo.ashx?20100422T1216486111Nycomed News RSS feedhttp://www.tpi.takeda.com/media/Mon, 22 Apr 2013 08:08:17 GMTMon, 22 Apr 2013 08:08:17 GMTTakeda and Sanofi Sign Co-promotion Agreement to Expand Reach of Diabetes Treatment Alogliptin in China http://www.tpi.takeda.com/media/news-releases/2013/takeda-and-sanofi-sign-co-promotion-agreement-to-expand-reach-of--alogliptin/Mon, 22 Apr 2013 08:08:17 GMThttp://www.tpi.takeda.com/media/news-releases/2013/takeda-and-sanofi-sign-co-promotion-agreement-to-expand-reach-of--alogliptin/Takeda Launches New Subsidiary in Ecuador http://www.tpi.takeda.com/media/news-releases/2013/takeda-launches-new-subsidiary-in-ecuador/Thu, 21 Mar 2013 09:20:20 GMThttp://www.tpi.takeda.com/media/news-releases/2013/takeda-launches-new-subsidiary-in-ecuador/NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84http://www.tpi.takeda.com/media/news-releases/2013/nps-pharmaceuticals-and-takeda-revise-agreements/Tue, 19 Mar 2013 09:33:24 GMThttp://www.tpi.takeda.com/media/news-releases/2013/nps-pharmaceuticals-and-takeda-revise-agreements/Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Unionhttp://www.tpi.takeda.com/media/news-releases/2013/takeda-submits-marketing-authorisation-application-for-vedolizumab/Thu, 07 Mar 2013 06:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2013/takeda-submits-marketing-authorisation-application-for-vedolizumab/Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)http://www.tpi.takeda.com/media/news-releases/2013/takeda-receives-fda-approval-for-three-new-type-2-diabetes-therapies/Sat, 26 Jan 2013 06:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2013/takeda-receives-fda-approval-for-three-new-type-2-diabetes-therapies/Takeda Establishes New Trading Company and Reinforces Business Structure in Chinahttp://www.tpi.takeda.com/media/news-releases/2013/takeda-establishes-new-trading-company-and-reinforces-business-structure-in-china/Tue, 22 Jan 2013 06:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2013/takeda-establishes-new-trading-company-and-reinforces-business-structure-in-china/Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceuticalhttp://www.tpi.takeda.com/media/news-releases/2012/takeda-to-sell-non-colcrys-url-pharma-generic-business-to-sun-pharmaceutical/Tue, 18 Dec 2012 06:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2012/takeda-to-sell-non-colcrys-url-pharma-generic-business-to-sun-pharmaceutical/Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)http://www.tpi.takeda.com/media/news-releases/2012/takeda-and-millennium-announce-european-conditional-marketing-authorisation-for-adcetris/Wed, 31 Oct 2012 06:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2012/takeda-and-millennium-announce-european-conditional-marketing-authorisation-for-adcetris/Takeda Completes its Russian Pharmaceutical Manufacturing Facilityhttp://www.tpi.takeda.com/media/news-releases/2012/takeda-completes-its-russian-pharmaceutical-manufacturing-facility/Wed, 12 Sep 2012 05:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2012/takeda-completes-its-russian-pharmaceutical-manufacturing-facility/Revestive® (teduglutide) receives European marketing authorization for the treatment of adults with Short Bowel Syndrome (SBS)http://www.tpi.takeda.com/media/news-releases/2012/revestive-receives-european-marketing-authorization/Wed, 05 Sep 2012 05:00:00 GMThttp://www.tpi.takeda.com/media/news-releases/2012/revestive-receives-european-marketing-authorization/